Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 207117, held by Glenmark Pharms Ltd. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 207117 (Triamcinolone Acetonide), held by Glenmark Pharms Ltd, was first approved by FDA on Aug 5, 2016, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Triamcinolone Acetonide Cream USP, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 5, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.1% · cream;topical | Triamcinolone Acetonide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
